LUMBY, British Columbia, April 19 /PRNewswire-FirstCall/ -- avVaa World Health Care Products, Inc. , a biotech company offering global customers therapeutic skin and health care products, today issued the following shareholder update:
Dear Valued Shareholder,
Since we last updated shareholders, management has remained focused on increasing our presence in both Canada and the U.S. by establishing strategic relationships in key regions of North America. There is such a critical need for effective therapeutic skin care products designed to ease the symptoms for a growing number of consumers suffering from psoriasis, eczema and other skin related disorders.
One important strategic relationship with a successful marketing company headquartered in the United States, has created a host of targeted sales opportunities for avVaa, including a beta test that is ongoing now in a large U.S. city at a number of locations for a major drug store chain. The feedback on the beta testing to date from the national retailer points only to sales successes and additional store rollouts based upon positive response.
avVaa products are also being offered directly to our target markets through Internet sales, enabling avVaa to gather critical information to ensure future full scale roll-out successes. Additionally, we are currently working to secure contractual relationships to sell avVaa products through national direct-to-consumer forums as well as online retailers.
For the past six months, initiatives have been underway to introduce a full line of avVaa cosmetic skin care products in a revolutionary way -- in both big box, high volume retailers as well as traditional upscale retailers. In fact, we expect to have avVaa cosmetic products in at least one very well known chain by the end of this year.
For all of our product offerings, clinical studies are critical to gaining validity and marketplace acceptance. I’m proud to announce that a number of patients have recently enrolled in an efficacy study that is being conducted by the University of Medicine and Dentistry of New Jersey in conjunction with one of the country’s leading dermatologists. Additional studies are under review and results are expected to open a number of strategic opportunities for avVaa.
In addition to marketing introductions to U.S. and Canadian retailers, avVaa management is focused on securing sufficient manufacturing capacity to allow for growth throughout North America. Several manufacturers have been targeted for a relationship with avVaa that will allow for scalable production and manufacturing as we aim for long-term success.
As growth in product distribution, manufacturing and marketing are critical to avVaa’s business plan, so is strategic long-term financing for continued success. In recent months, we have negotiated an important financing arrangement which will allow us to continue to roll out existing products, fund marketing costs associated with product launches, as well as continue the development of new applications, including products for insect bites and burn treatment that range from serious radiation and chlorine burns to relatively mild sun burns.
While careful attention is being focused on growing avVaa’s human health products, our newest line of pet and equine care products have been counting successes as well. Over the past several months, we have partnered with established distributors, including Galaman Ltd., for placement of our innovative veterinary and equine products in veterinary hospitals and clinics throughout Canada. avVaa is already benefiting from this agreement with an initial order placed by Galaman in February.
We also signed Needs N Desires, a mobile dog show retailer and well-recognized name in the dog show industry that is scheduled to attend more than 25 Canadian Kennel Club (CKC) dog shows in 2006. Significant product testing is well underway at the Schools of Veterinary Medicine at both Rutgers and Tufts universities in the United States that we will utilize to enhance this new line.
Significant progress has also been made in our efforts to find partners interested in marketing avVaa products under their own, established brand names. One major pet health company is reviewing a number of our products and avVaa is working toward a settlement by the end of the year. In human health, we are currently discussing private labeling with an established company that has secured shelf space in approx. 21,000 stores and would be an ideal partner for avVaa products.
avVaa will continue to introduce products throughout North America in a focused manner that best serves our consumers and the long term success of our Company. We look forward to continued partnership with our valued shareholders as we remain focused on core strategies; including developing high quality high value products, pursuing additional applications for our central technology and using world class people to exceed our goals.
Sincerely, Jack Farley, CEO About avVaa World Health Care Products
avVaa World Health Care Products is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers.
avVaa’s patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin line of skin care products through mass, food and drug channels in the United States and globally. The Company’s secondary line of equine and pet care related products are already being distributed throughout all of Canada. For more information, visit: http://www.avvaa.com or http://www.otcfn.com/avvw.
For additional information on avVaa contact Jack Farley CEO / President, at 1-866-772-8822 or visit: http://www.avvaa.com or http://www.otcfn.com/avvw.
Investor Relations: Merle Goertz (West Coast) of avVaa World Health Care Products, 1-604-688-2349; or Richard McCaffrey of OTC Financial Network, 1-781-444-6100 ext. 625
Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward- looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of AVVAA World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
avVaa World Health Care Products, Inc.
CONTACT: Jack Farley of avVaa, CEO / President, 1-866-772-8822; InvestorRelations - Merle Goertz of avVaa World Health Care Products, West Coast,+1-604-688-2349; or Richard McCaffrey of OTC Financial Network,+1-781-444-6100 ext. 625
Web site: http://www.avvaa.com/